tirzepatide phase 1 Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Tirzepatide for Medical Weight Loss

In July 2023, a new potential safety risk was identified associated with the GLP-1 receptor agonists exenatide, lixisenatide, liraglutide, dulaglutide and semaglutide, and the risk of suicidal thoughts and self-harm following an initial review of post-marketing reports

The response rate data reveals another important distinction

During the course of the trial, the number of participants increased to approximately 220 owing to an unexpected sharp drop in the screening failure percentage after recruitment closure

The rapid decline in lesion counts, especially between weeks 4 and 8, demonstrates the products potential in reducing acne-like lesions, contributing to an overall improvement in skin condition for patients with rosacea

(To date, research on pregnant women and GLP1 medications suggest it is not linked to more birth defects than insulin, but the full impact of fetal exposure is not yet known

In the study, researchers at the University of Virginia specifically investigated small-molecule GLP-1 receptor agonists, such as the Food and Drug Administration (FDA)-approved orforglipron, which can be taken orally and are cheaper to produce than their injectable counterparts